Market Closed -
Euronext Amsterdam
11:35:00 2024-06-20 am EDT
After market
01:43:16 pm
0.7545
EUR
+1.89%
0.753
-0.20%
Pharming N : Publication of Voting Results of the AGM 2024
May 23, 2024 at 04:23 am EDT
Pharming AGM May 21, 2024: Voting Results
75.689.426 shares were present and/or represented, which represented 11.19% of issued capital
FOR
%
AGAINST
%
TOTAL
ABSTAIN
2.b
70,410,032
95.62
3,227,282
4.38
75,379,579
309,847
2.e
74,133,543
99.31
512,087
0.69
75,388,179
301,247
2.f
73,201,810
98.07
1,441,152
1.93
75,389,579
299,847
3
70,073,020
94.17
4,335,193
5.83
75,357,879
331,547
4.a
67,297,323
90.23
7,286,863
9.77
75,369,479
319,947
4.b
73,855,988
98.88
839,450
1.12
75,369,479
319,947
5.
69,755,857
93.49
4,854,686
6.51
75,388,479
300,947
6.
71,821,038
96.33
2,737,274
3.67
75,369,479
319,947
Disclaimer
Pharming Group NV published this content on
23 May 2024 and is solely responsible for the information contained therein. Distributed by
Public , unedited and unaltered, on
23 May 2024 08:22:02 UTC .
Pharming Group Flags Delay in EU Review of Rare Immunodeficiency Drug
May. 31
MT
Pharming Group N.V. Provides Update on Ongoing Regulatory Review of Leniolisib for the Treatment of Apds in the European Union
May. 30
CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call
May. 21
Transcript : Pharming Group N.V., Q1 2024 Earnings Call, May 08, 2024
May. 08
Pharming Group N.V. Provides Revenue Guidance for 2024
May. 08
CI
Pharming Group N.V. Reports Earnings Results for the First Quarter Ended March 31, 2024
May. 08
CI
Pharming Group to Buy Back EUR123 Million of Bonds due 2025
Apr. 22
MT
Pharming Group to Issue EUR100 Million Convertible Bonds, Repurchase EUR125 Million Bonds
Apr. 18
MT
Pharming Group N.V. announced that it expects to receive ?100 million in funding
Apr. 17
CI
Pharming Group N.V. Announces Completion of Enrollment in Pediatric Clinical Trial of Leniolisib
Apr. 08
CI
Pharming Group Finishes Enrolling Patients for Phase 3 Pediatric Testing of its Treatment for Rare Auto-Immune Disorder
Apr. 08
MT
Pharming Group N.V. Provides Earnings Guidance for the Year 2024
Mar. 14
CI
Pharming Group Seeks Acquisitions
Mar. 14
CI
Transcript : Pharming Group N.V., Q4 2023 Earnings Call, Mar 14, 2024
Mar. 14
Pharming Group N.V. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023
Mar. 14
CI
Pharming Group N.V. Reports Earnings Results for the Full Year Ended December 31, 2023
Mar. 14
CI
RBC Raises Price Target on Pharming Group to EUR2.10 From EUR1.95, Keeps Outperform Rating
Jan. 09
MT
Pharming Group Announces Development Plans for Leniolisib for Additional Primary Immunodeficiencies
Dec. 15
CI
Pharming Group Plans Phase 2 Trial for Immune System Drug in 2024
Dec. 13
MT
Pharming Group Plans to Develop Leniolisib for Additional Primary Immunodeficiencies Following Engagement With FDA
Dec. 13
MT
Pharming Group Expects EU Panel Opinion in 2024 for Rare Immunodeficiency Treatment
Nov. 10
MT
Transcript : Pharming Group N.V., Q3 2023 Earnings Call, Oct 26, 2023
23-10-26
Pharming Group N.V. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023
23-10-26
CI
Pharming Group N.V. Appoints Richard Peters as Non-Executive Director
23-09-25
CI
Transcript : Pharming Group N.V. - Shareholder/Analyst Call
23-09-25
Duration Auto. 2 months 3 months 6 months 9 months 1 year 2 years 5 years 10 years Max.
Period Day Week
More charts
Pharming Group N.V. is a global biopharmaceutical company dedicated to transforming the lives of patients with rare, debilitating, and life-threatening diseases. The Group is commercializing and developing an innovative portfolio of protein replacement therapies and precision medicines, including small molecules, biologics, and gene therapies that are in early to late-stage development.
Pharming Group N.V. serves patients in over 30 markets in North America, Europe, the Middle East, Africa, and Asia/Pacific.
More about the company
Last Close Price
0.7405
EUR
Average target price
1.875
EUR
Spread / Average Target
+153.21%
Consensus
1st Jan change
Capi.
-26.82% 536M +51.54% 803B -5.93% 351B +18.79% 324B +11.22% 303B +16.96% 243B +2.25% 228B +11.15% 217B +7.18% 164B -3.09% 155B
Other Pharmaceuticals
+951% of historical performance
More than 20 years at your side
Our Experts are here for you
OUR EXPERTS ARE HERE FOR YOU
Monday - Friday 9am-12pm / 2pm-6pm GMT + 1